Intellia Therapeutics Inc (NTLA)
13.42
-1.18%
Intellia Therapeutics Inc (NTLA) is currently trading at $13.42. This represents a loss of 1.18% from the previous session. With a market capitalization of $1.55B, NTLA is a key component of the Health Care sector. Investors looking to trade NTLA should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade NTLA commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Intellia Therapeutics Inc (NTLA) shows a bearish trend. Analysts are watching the 13.93 level closely.
Fundamentals
Mkt Cap1.55B
P/E Ratio0.0000
Volume2,284,798
60-Day Technical Chart
Advanced Charting
Need more indicators for NTLA? Use the world's #1 platform.
Open NTLA on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $13
| Metric |
NTLA -1.18% |
F +1.62% |
AAL +1.29% |
SMR -1.86% |
|---|---|---|---|---|
| Price | $13.42 | $14.43 | $13.32 | $13.18 |
| Mkt Cap | $1.55B | $57.57B | $8.80B | $3.99B |
| - | View → | View → | View → |
Latest Headlines
How to watch Intellia’s March investor talks at three healthcare conferences
Stock Titan • Feb 24, 2026
Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal
Yahoo Finance • Feb 2, 2026
Why This Beleaguered Gene-Editing Stock Just Surged
Investor's Business Daily • Jan 27, 2026
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock Trajectory In 2026 (NTLA)
Seeking Alpha • Feb 5, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire • Feb 6, 2026
● Gemini Agentic AI Analyst Insight for NTLA
Market Education
- Want to be a Wall street billionaire, take their investing advice Jul 19, 2023
- Finding Stocks in the Squeeze Zone: Using Finviz Jul 30, 2023
- Stocks with Cash and Low Debt Dec 10, 2023
External Research